Ethypharm Expands Treatment Options for IBD Patients

Ethypharm, a renowned pharmaceutical company, has recently made a significant acquisition in the field of medicine. Through its Chinese affiliate, Shanghai Ethypharm Pharmaceuticals Ltd, Ethypharm has obtained the suppository form of Mesalazine from Jiangsu Anbison Pharmaceutical in China. Mesalazine is a vital medication used to treat Inflammatory Bowel Diseases (IBD) such as ulcerative colitis and Crohn's disease.

This strategic move by Ethypharm aligns with its goal to enhance its presence in key markets like Europe and China, as well as globally through its distribution network. By adding the Mesalazine suppository form to its product portfolio, Ethypharm aims to meet the demand for quality treatments in China and extend the life cycle of its leading product, Etiasa®.

With a focus on central nervous system disorders, hospital care, and internal medicine, Ethypharm is dedicated to improving patients' lives and contributing positively to society and the environment. The company's commitment to providing essential medicines is evident in its operations, which include six production sites across France, the UK, Spain, and China.

Operating in 68 countries, Ethypharm markets its products directly in Europe and China while forming strategic partnerships in other regions. By collaborating closely with healthcare professionals and authorities, Ethypharm ensures the appropriate use of its medicines and facilitates patient access to them.

Ethypharm's acquisition of the Mesalazine suppository form marks a significant step towards expanding treatment options for patients with Inflammatory Bowel Diseases. With a strong focus on improving patient outcomes and a commitment to providing essential medicines, Ethypharm continues to make strides in the pharmaceutical industry, benefiting individuals worldwide.